Edited by Francesco Pezzella, Professor of Tumour Pathology, University of Oxford, UK, Mahvash Tavassoli, Professor of Molecular Oncology, King's College London, UK, and David J. Kerr, Professor of Cancer Medicine, University of Oxford, UK; and Adjunct Professor of Medicine, Weill Cornell College of Medicine, New York, USA
Francesco Pezzella is Professor of Tumour Pathology at the University of Oxford, UK, and Consultant Pathologist at the Oxford University Hospitals. His early work focused on the pathology of HIV and its effect on lymph nodes, followed by the molecular alterations of non-Hodgkin's Lymphoma. His research then turned to cancer and blood vessels, whereby he discovered the non-angiogenic pathway of the growth of human cancers, leading to a change in one of the hallmarks of cancer. Professor Pezzella continues to specialise in haematopathology and has published over 200 papers.
Mahvash Tavassoli is Professor of Molecular Oncology at King's College London, UK. She has held several positions internationally, including at the Fred Hutchinson Cancer Research Centre in Seattle, the University of Sussex, and the Max Planck institute in Munich. Professor Tavassoli's early research focused on understanding the signaling and apoptosis pathways which are deregulated in cancer, before shifting towards the clinical application of her lab work. She currently leads a research team at KCL focused on developing genetic tests for the early detection and prediction of patient response to radiotherapy in head and neck cancer. They aim to develop more effective, less toxic cancer therapeutics.
David J. Kerr is Professor of Cancer Medicine, at the University of Oxford, UK, and Adjunct Professor of Medicine at Weill Cornell College of Medicine in New York, USA. Professor Kerr has made a sustained and internationally recognised contribution to cancer care and research in the field of medical oncology over the past three decades. He has published over 400 papers in high profile journals, authored over twenty books, and has been awarded four prestigious, international research prizes, including the NHS's first Nye Bevan award for Innovation. His scientific standing has been recognised by election as Fellow of the Royal College of Physicians, Fellow of Academy of Medical Sciences, President of the European Society of Medical Oncology (2009-2011), and Founding Fellow of the European Academy of Cancer Sciences.
Balkees Abderrahman, Department of Breast Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, USA
Margaret Ashcroft, Department of Medicine, University of Cambridge, Cambridge, UK
Nicholas Athanasou, Nuffield Department of Orthopaedics, Rheumatology, and Musculoskeletal Science, University of Oxford, Oxford, UK
Michael Baumann, Cancer Research Center (DKFZ), Heidelberg, Germany and Department of Radiotherapy and Radiation Oncology, Faculty of Medicine and University Hospital Carl Gustav Carus, Technische Universität Dresden, Germany
Karim Bensaad, Department of Oncology, University of Oxford, Oxford, UK
Jessica Bullenkamp, Molecular and Clinical Sciences Research Institute, St. George's University London, London, UK
Giacomo Buscemi, Department of Biosciences, University of Milan, Milan, Italy
Simon Carr, Department of Oncology, University of Oxford, Oxford, UK
David N. Church, Tumour Genomics and Immunology Group, Wellcome Centre for Human Genetics, University of Oxford, Oxford, UK
Laura C. Collopy, Cancer Institute, Faculty of Medical Sciences, University College London, London, UK
Pedro Cutillas, Cell Signalling and Proteomics Group, Barts Cancer Institute (CRUK Centre), Queen Mary University of London, London, UK
Blossom Damania, Lineberger Comprehensive Cancer Center and Department of Microbiology and Immunology, School of Medicine, University of North Carolina, USA
Dirk P. Dittmer, Lineberger Comprehensive Cancer Center and Department of Microbiology and Immunology, School of Medicine, University of North Carolina, USA
Tom Donnem, Department of Oncology, University Hospital of North Norway and the Arctic University of Norway, Tromso, Norway
Anna Dubrovska, German Cancer Consortium (DKTK) Dresden and German Cancer Research Center (DKFZ) Heidelberg, Germany
Nadège Gaborit, Institut de Recherche en Cancérologie de Montpellier, Université de Montpellier, Montpellier, France
Kevin Gatter, Nuffield Division of Clinical Laboratory Sciences, Radcliffe Department of Medicine, University of Oxford, Oxford, UK
Mark A. Glaire, Tumour Genomics and Immunology Group, Wellcome Centre for Human Genetics, University of Oxford, Oxford, UK
Betty Gration, MRC Molecular Haematology Unit, Radcliffe Department of Medicine, Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, UK
Daniel Haller, Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, USA
Adrian L. Harris, Department of Oncology, University of Oxford, Oxford, UK
Edward Hookway, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK
Jiangting Hu, Radcliffe Department of Medicine, University of Oxford, UK
V. Craig Jordan, Department of Breast Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, USA
Robert Kerbel, Biological Sciences Platform, Sunnybrook Research Institute, Department of Medical Biophysics, University of Toronto, Toronto, Canada
David Kerr, Professor of Cancer Medicine, University of Oxford, UK, and Adjunct Professor of Medicine, Weill Cornell College of Medicine, New York, USA
Benedikt M. Kessler, Target Discovery Institute, Nuffield Department of Medicine, University of Oxford, Oxford, UK
Mechthild Krause, German Cancer Consortium (DKTK) Dresden and German Cancer Research Center (DKFZ) Heidelberg, Germany
Nicholas La Thangue, Department of Oncology, University of Oxford, Oxford, UK
Andrew P. Mazar, Monopar Therapeutics, Wilmette, USA
W.E. Mesker, Department of Surgery, Leiden University Medical Center, Leiden, the Netherlands
Kingsley Micklem, Nuffield Division Clinical Laboratory Science, Radcliffe Department of Medicine, University of Oxford, Oxford, UK
Gwennaëlle C. Monnot, Ludwig Cancer Research Center, Department of Fundamental Oncology, Faculty of Biology and Medicine, University of Lausanne, Lausanne, Switzerland
Udo Oppermann, Nuffield Department of Orthopaedics, Rheumatology, and Musculoskeletal Science, University of Oxford, Oxford, UK
Francesco Pezzella, Professor of Tumour Pathology, University of Oxford, Oxford, UK
David H. Phillips, Department of Analytical, Environmental and Forensic Sciences, School of Population Health and Environmental Sciences, King's College London, London, UK
Karen Pulford, Emeritus Reader in Immunodiagnostics, Nuffield Division of Clinical Laboratory Sciences, Radcliffe Department of Medicine, University of Oxford, Oxford, UK
Lynn Quek, MRC Molecular Haematology Unit, Radcliffe Department of Medicine, Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, UK
Chao-Nan Qian, Department of Nasopharyngeal Carcinoma, State Key Laboratory of Oncology South China, Sun Yat-Sen University Cancer Center, Guangzhou, China
Andrea Rasola, Department of Biomedical Sciences, University of Padova, Padova, Italy
Pedro Romero, Ludwig Cancer Research Center, Department of Fundamental Oncology, Faculty of Biology and Medicine, University of Lausanne, Lausanne, Switzerland
Almut Schulze, Department of Biochemistry and Molecular Biology, Biocenter, University of Würzburg, Würzburg, Germany
Connor Sweeney, MRC Molecular Haematology Unit, Radcliffe Department of Medicine, Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, UK
Mahvash Tavassoli, Professor of Molecular Oncology, King's College London, London, UK
R.A.E.M. Tollenaar, Department of Surgery, Leiden University Medical Center, Leiden, the Netherlands
Kazunori Tomita, Cancer Institute, Faculty of Medical Sciences, University College London, London, UK
Andrey Ugolkov, Division of Hematology and Oncology, Feinberg School of Medicine, Northwestern University, Chicago, USA
Pieter-Jan van Dam, Faculty of Medicine and Health Sciences, University Antwerp, Antwerp, Belgium
Steven Van Laere, HistoGeneX NV, Antwerp, Belgium
Lieven Verbeke, Department of Information Technology, Ghent University, Ghent, Belgium
Jaap Verweij, Department of Medical Oncology, Erasmus University Medical Centre, Rotterdam, the Netherlands
Paresh Vyas, MRC Molecular Haematology Unit, Radcliffe Department of Medicine, Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, UK
Herman Waldmann, Sir William Dunn School of Pathology, University of Oxford, Oxford, UK
Yan-Qun Xiang, Department of Nasopharyngeal Carcinoma, Sun Yat-Sen University Cancer Center, Guangzhou, China
Yosef Yarden, Department of Biological Regulation, Weizmann Institute of Science, Rehovot, Israel
